首页> 美国卫生研究院文献>other >Protocells: Modular mesoporous silica nanoparticle-supported lipid bilayers for drug delivery
【2h】

Protocells: Modular mesoporous silica nanoparticle-supported lipid bilayers for drug delivery

机译:原始细胞:模块化介孔二氧化硅纳米颗粒支持的脂质双层用于药物递送

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mesoporous silica nanoparticle supported-lipid bilayers, termed ‘protocells,’ represent a potentially transformative class of therapeutic and theranostic delivery vehicles. The field of targeted drug delivery poses considerable challenges that cannot be addressed with a single ‘magic bullet’. Consequently the protocell has been designed as a modular platform composed of interchangeable biocompatible components. The mesoporous silica core can have variable size and shape to direct biodistribution and controlled pore size and surface chemistry to accommodate diverse cargos. The encapsulating supported lipid bilayer can be modified with targeting and trafficking ligands as well as PEG to effect selective binding, endosomal escape of cargo, drug efflux prevention, and potent therapeutic delivery, while maintaining in vivo colloidal stability. This mini-review describes the individual components of the platform, including the mesoporous silica nanoparticle core and supported lipid bilayer, their assembly (by multiple techniques) into a protocell, and the combined, often synergistic, performance of the protocell based on in vitro and in vivo studies including assessment of biocompatibility and toxicity. We close by commenting on the many emerging variations of the protocell theme and the future directions for protocell research.
机译:介孔二氧化硅纳米颗粒支持的脂质双层,称为“原生细胞”,代表了治疗和治疗学治疗载体的潜在转化类型。有针对性的药物输送领域提出了巨大的挑战,而单个“魔术子弹”是无法解决的。因此,原始细胞已被设计为由可互换的生物相容性成分组成的模块化平台。中孔二氧化硅核可具有可变的大小和形状以指导生物分布,并控制孔径和表面化学性质以适应各种货物。可以用靶向和运输配体以及PEG修饰包封的支持的脂质双层,以实现选择性结合,货物的内体逸出,药物外排防止和有效的治疗递送,同时保持体内胶体稳定性。这份小型回顾介绍了平台的各个组成部分,包括介孔二氧化硅纳米颗粒核心和支持的脂质双层,它们通过多种技术组装(通过多种技术)到原生细胞中,以及基于体外和体外实验的原生细胞的组合(通常是协同)性能体内研究,包括评估生物相容性和毒性。在结束时,我们将评论原始细胞主题的许多新兴变化以及原始细胞研究的未来方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号